To evaluate role of procalcitonin in detecting sepsis in patients with liver failure
Not Applicable
- Conditions
- Health Condition 1: K742- Hepatic fibrosis with hepatic sclerosis
- Registration Number
- CTRI/2024/06/069424
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age more than 18 years
Patients diagnosed with cirrhosis.
Patient with evidence of Systemic inflammatory response syndrome and presence of infection.
Exclusion Criteria
Patients diagnosed as Acute-on-chronic liver failure as per APASL definition.
Patients who are diagnosed with HCC
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the spectrum of various infections in patients with <br/ ><br>decompensated cirrhosis. <br/ ><br>Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method To assess the efficacy of procalcitonin as a marker in detecting <br/ ><br>sepsis in patients with decompensated cirrhosis.Timepoint: 6 months